ID | 65720 |
フルテキストURL | |
著者 |
Yamamoto, Yukichika
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Otsuka, Yuki
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Tokumasu, Kazuki
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
publons
researchmap
Sunada, Naruhiko
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Nakano, Yasuhiro
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Honda, Hiroyuki
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sakurada, Yasue
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hasegawa, Toru
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hagiya, Hideharu
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
researchmap
Otsuka, Fumio
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
|
抄録 | Objective: The most common symptom of post-acute coronavirus disease 2019 (COVID-19) is fatigue, and it potentially leads to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); however, a specific prognosticator is lacking. We aimed to elucidate the clinical characteristics of patients who developed ME/CFS after COVID-19. Methods: In this retrospective observational study, patients who visited Okayama University Hospital for long COVID between February 2021 and March 2022 were investigated. Results: Of the 234 patients, 139 (59.4%) had fatigue symptoms. Fifty patients with fatigue symptoms (21.4%) met the criteria for ME/CFS (ME/CFS group), while the other 89 patients did not (non-ME/CFS group); 95 patients had no fatigue complaints (no-fatigue group). Although the patients’ backgrounds were not significantly different between the three groups, the ME/CFS group presented the highest scores on the self-rating symptom scales, including the Fatigue Assessment Scale (FAS), EuroQol, and the Self-Rating Depression Scale (SDS). Furthermore, serum ferritin levels, which were correlated with FAS and SDS scores, were significantly higher in the ME/CFS group (193.0 μg/L, interquartile range (IQR): 58.8–353.8) than in the non-ME/CFS group (98.2 μg/L, 40.4–251.5) and no-fatigue group (86.7 μg/L, 37.5–209.0), and a high serum ferritin level was prominent in female patients. Endocrine workup further showed that the ME/CFS group had higher thyrotropin levels but lower growth hormone levels in serum and that insulin-like growth factor-I levels were inversely correlated with ferritin levels (R = −0.328, p < 0.05). Conclusions: Serum ferritin level is a possible predictor of the development of ME/CFS related to long COVID, especially in female patients.
|
キーワード | COVID-19
ferritin
insulin-like growth factor-I (IGF-I)
long COVID
myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
|
発行日 | 2023-07-18
|
出版物タイトル |
Journal of Clinical Medicine
|
巻 | 12巻
|
号 | 14号
|
出版者 | MDPI
|
開始ページ | 4737
|
ISSN | 2077-0383
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2023 by the authors.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.3390/jcm12144737
|
ライセンス | https://creativecommons.org/licenses/by/4.0/
|
Citation | Yamamoto, Y.; Otsuka, Y.; Tokumasu, K.; Sunada, N.; Nakano, Y.; Honda, H.; Sakurada, Y.; Hasegawa, T.; Hagiya, H.; Otsuka, F. Utility of Serum Ferritin for Predicting Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome in Patients with Long COVID. J. Clin. Med. 2023, 12, 4737. https://doi.org/ 10.3390/jcm12144737
|
助成機関名 |
Japan Society for the Promotion of Science
|
助成番号 | JP22K20927
|